A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Graft-versus-host disease; Hodgkin's disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Polycythaemia vera
- Focus Therapeutic Use
- 06 Oct 2015 Biomarkers information updated
- 17 Apr 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 21 Sep 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.